View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 48. 1088
  • 2 Magyar Tudományos Akadémia Molekuláris Medicina Kutatócsoport Budapest
Open access

A peptikus fekélybetegség kóroktana és klinikai megjelenési formái átalakulóban vannak. A H. pylori -fertőzés mellett a nem szteroid gyulladáscsökkentők és a kis dózisú acetilszalicilsav-kezelés kóroki szerepe ismert. A H. pylori -pozitív fekélybetegség a baktérium eradikációjával gyógyítható. Az NSAID-fekély megelőzésére a savszekréció-gátló adását pedig a gyomor-bél rendszeri, valamint szív-ér rendszeri kockázati tényezők határozzák meg. A számos kóroki tényező és az új, hatékony kezelési módok alkalmazása ellenére továbbra is vannak megválaszolatlan kérdések. Előtérbe kerültek az NSAID- és a H. pylori- negatív fekélyek, amelyek száma növekszik, kezelésük tisztázásra vár. A H. pylori -eradikáció sikertelensége is gyakoribbá vált, az optimális kezelési mód hiányzik.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Maltfertheiner, P., Chan, F. K. L., McColl, K. E. L.: Peptic ulcer disease. Lancet, 2009, 374 , 1449–1461.

    McColl K. E. L. , 'Peptic ulcer disease ' (2009 ) 374 Lancet : 1449 -1461.

  • Yuan, Y., Padol, I. T., Hunt, R. H.: Peptic ulcer today. Nat. Clin. Pract. Gastroenterol. Hepatol., 2006, 3 , 80–89.

    Hunt R. H. , 'Peptic ulcer today ' (2006 ) 3 Nat. Clin. Pract. Gastroenterol. Hepatol. : 80 -89.

    • Search Google Scholar
  • Gasztroenterológiai Útmutató 2007. (Szerk.: Tulassay Zs. ): A fekélybetegség (a nyombél- és gyomorfekély) ellátási protokollja. Budapest, 2007, 76–83.

  • Sonneberg, A.: Time trends of ulcer mortality in Europe. Gastroenterology, 2007, 132 , 2320–2327.

    Sonneberg A. , 'Time trends of ulcer mortality in Europe ' (2007 ) 132 Gastroenterology : 2320 -2327.

    • Search Google Scholar
  • Kang, J. Y., Majeed, A.: Peptic ulcer-time trends at the turn of the millennium. Dig. Liver Dis., 2004, 36 , 570–571.

    Majeed A. , 'Peptic ulcer-time trends at the turn of the millennium ' (2004 ) 36 Dig. Liver Dis. : 570 -571.

    • Search Google Scholar
  • Bardhan, K. D., Royston, C.: Time, change and peptic ulcer disease in Rotherham, UK. Dig. Liver Dis., 2008, 40 , 540–546.

    Royston C. , 'Time, change and peptic ulcer disease in Rotherham, UK ' (2008 ) 40 Dig. Liver Dis. : 540 -546.

    • Search Google Scholar
  • Zapata-Colindres, J. C., Zepeda-Gomez, S., Montano-Loza, A. és mtsai: The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease. Can. J. Gastroenterol., 2006, 20 , 277–280.

    Montano-Loza A. , 'The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease ' (2006 ) 20 Can. J. Gastroenterol. : 277 -280.

    • Search Google Scholar
  • Kusters, J. G., van Vliet, A. H. M., Kuipers, E. J.: Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev., 2006, 19 , 449–490.

    Kuipers E. J. , 'Pathogenesis of Helicobacter pylori infection ' (2006 ) 19 Clin. Microbiol. Rev. : 449 -490.

    • Search Google Scholar
  • Gasztroenterológiai Útmutató 2007. (Szerk.: Tulassay Zs. ): A Helicobacter pylori-fertőzés epidemiológiája és a diagnosztika irányelvei. A Helicobacter pylori fertőzés kezelésének időszerű kérdései. Budapest, 2007, 54–63.

  • Suzuki, H., Hibi, T., Marshall, B. J.: Helicobacter pylori: present status and future prospects in Japan. J. Gastroenterol., 2007, 42 , 1–15.

    Marshall B. J. , 'Helicobacter pylori: present status and future prospects in Japan ' (2007 ) 42 J. Gastroenterol. : 1 -15.

    • Search Google Scholar
  • Gisbert, J. P., Calvet, X.: Helicobacter pylori-negative duodenal ulcer disease. Aliment. Pharmacol. Ther., 2009, 30 , 791–815.

    Calvet X. , 'Helicobacter pylori-negative duodenal ulcer disease ' (2009 ) 30 Aliment. Pharmacol. Ther. : 791 -815.

    • Search Google Scholar
  • Wilcox, C. M., Allison, J., Benzuly, K. és mtsai: Consensus development conference on the use of nonsteroidal antiinflammatory agents, including cyclooxgenas-2 enzyme inhibitors and aspirin. Clin. Gastroenterol. Hepatol., 2006, 4 , 1082–1089.

    Benzuly K. , 'Consensus development conference on the use of nonsteroidal antiinflammatory agents, including cyclooxgenas-2 enzyme inhibitors and aspirin ' (2006 ) 4 Clin. Gastroenterol. Hepatol. : 1082 -1089.

    • Search Google Scholar
  • Frech, E. J., Go, M. F.: Treatment and chemoprevention of NSAID-asociated gastrointestinal complications. Ther. Clin. Risk Manag., 2009, 5 , 65–73.

    Go M. F. , 'Treatment and chemoprevention of NSAID-asociated gastrointestinal complications ' (2009 ) 5 Ther. Clin. Risk Manag. : 65 -73.

    • Search Google Scholar
  • Moore, R. A., Derry, S., Phillips, C. J. és mtsa: Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2-selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical parctice. BMC Musculoskeletal Disorders, 2006, 7 , 79–91.

    Phillips C. J. , 'Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2-selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical parctice ' (2006 ) 7 BMC Musculoskeletal Disorders : 79 -91.

    • Search Google Scholar
  • Hawkey, C. J., Langman, M. J. S.: Non-steroidal anti-inflammatory drugs: overall risk and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut, 2003, 52 , 600–608.

    Langman M. J. S. , 'Non-steroidal anti-inflammatory drugs: overall risk and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors ' (2003 ) 52 Gut : 600 -608.

    • Search Google Scholar
  • Gasztroenterológiai Útmutató 2007. (Szerk.: Tulassay Zs. ): A nem szteroid gyulladáscsökkentők gastrointestinalis mellékhatásainak megelőzése és kezelése. Klinikai Irányelvek Kézikönyve. Budapest, 2007, 68–70.

  • Ong, C. K. S., Lirk, P., Tan, C. H. és mtsa: An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin. Med. Res., 2007, 5 , 19–34.

    Tan C. H. , 'An evidence-based update on nonsteroidal anti-inflammatory drugs ' (2007 ) 5 Clin. Med. Res. : 19 -34.

    • Search Google Scholar
  • Becker, J. C., Domschke, W., Pohle, T.: Current approaches to prevent NSAID-induced gastropathy-COY selectivity and beyond. Br. J. Clin. Pharmacol., 2004, 58 , 587–600.

    Pohle T. , 'Current approaches to prevent NSAID-induced gastropathy-COY selectivity and beyond ' (2004 ) 58 Br. J. Clin. Pharmacol. : 587 -600.

    • Search Google Scholar
  • Mégraud, F., Lehours, P.: Helicobacter pylori detection and antimicrobial susceptibility testing. Clin. Microbiol. Rev., 2007, 20 , 280–322.

    Lehours P. , 'Helicobacter pylori detection and antimicrobial susceptibility testing ' (2007 ) 20 Clin. Microbiol. Rev. : 280 -322.

    • Search Google Scholar
  • Gasztroenterológiai Útmutató 2009. (Szerk.: Tulassay Zs. ): A Helicobacter pylori fertőzés epidemiológiája és diagnosztikai irányelvei. Budapest, 2009, 35–37.

  • Joo, M., Kwak, J. E., Chang, S. H. és mtsai: Helicobacter heilmannii -associated gastritis: Clinicopathologic findings and comparison with Helicobacter pylori -associated gastritis. J. Korean Med. Sci., 2007, 22 , 63–69.

    Chang S. H. , 'Helicobacter heilmannii-associated gastritis: Clinicopathologic findings and comparison with Helicobacter pylori-associated gastritis ' (2007 ) 22 J. Korean Med. Sci. : 63 -69.

    • Search Google Scholar
  • Herszényi L.: Helicobacter pylori negatív fekélyek. Hippocrates, 2003, 5 , 13–17.

    Herszényi L. , 'Helicobacter pylori negatív fekélyek ' (2003 ) 5 Hippocrates : 13 -17.

  • Chow, D. K., Sung, J. J.: Non-NSAID non-H. pylori ulcer disease. Best Res. Clin. Gastroenterol., 2009, 23 , 3–9.

    Sung J. J. , 'Non-NSAID non-H. pylori ulcer disease ' (2009 ) 23 Best Res. Clin. Gastroenterol. : 3 -9.

    • Search Google Scholar
  • Malfertheiner, P., Megraud, F., O’Morain, C. és mtsai, The European Helicobacter pylori Study Group: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007, 56 , 772–781.

    O’Morain C. , 'Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report ' (2007 ) 56 Gut : 772 -781.

    • Search Google Scholar
  • Wolle, K., Malfertheiner, P.: Treatment of Helicobacter pylori. Best Pract. Res. Clin. Gastroenterol., 2007, 21 , 315–324.

    Malfertheiner P. , 'Treatment of Helicobacter pylori ' (2007 ) 21 Best Pract. Res. Clin. Gastroenterol. : 315 -324.

    • Search Google Scholar
  • Hagymási K., Tulassay Zs.: A Helicobacter pylori eradikációjának legújabb szempontjai és a bakteriális rezisztencia jelentősége. Orv. Hetil., 2008, 149 , 2029–2035.

    Tulassay Zs. , 'A Helicobacter pylori eradikációjának legújabb szempontjai és a bakteriális rezisztencia jelentősége ' (2008 ) 149 Orv. Hetil. : 2029 -2035.

    • Search Google Scholar
  • Tulassay, Zs., Kryszewszki, A., Dite, P. és mtsai: One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur. J. Gastroenterol. Hepatol., 2001, 13 , 1457–1465.

    Dite P. , 'One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease ' (2001 ) 13 Eur. J. Gastroenterol. Hepatol. : 1457 -1465.

    • Search Google Scholar
  • Tulassay, Zs., Stolte, M., Sjölund, M. és mtsai: Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients. Eur. J. Gastroent. Hepatol., 2008, 6 , 526–535.

    Sjölund M. , 'Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients ' (2008 ) 6 Eur. J. Gastroent. Hepatol. : 526 -535.

    • Search Google Scholar
  • Zullo, A., De Francesco, V., Hassan, C. és mtsai: The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut, 2007, 56 , 1353–1357.

    Hassan C. , 'The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis ' (2007 ) 56 Gut : 1353 -1357.

    • Search Google Scholar
  • Vakil, N., Megraud, F.: Eradication therapy for Helicobacter pylori. Gastroenterology, 2007, 133 , 985–1001.

    Megraud F. , 'Eradication therapy for Helicobacter pylori ' (2007 ) 133 Gastroenterology : 985 -1001.

    • Search Google Scholar
  • Gisbert, J. P.: “Rescue” regimens after Helicobacter pylori treatment failure. W. J. Gastroenterol., 2008, 14 , 5385–5402.

    Gisbert J. P. , '“Rescue” regimens after Helicobacter pylori treatment failure ' (2008 ) 14 W. J. Gastroenterol. : 5385 -5402.

    • Search Google Scholar
  • Cairns, J. A.: The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks. Can. J. Cardiol., 2007, 23 , 125–131.

    Cairns J. A. , 'The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks ' (2007 ) 23 Can. J. Cardiol. : 125 -131.

    • Search Google Scholar
  • Chan, F. K., Hung, L. C. T., Suen, B. Y. és mtsai: Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology, 2004, 127 , 1038–1043.

    Suen B. Y. , 'Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial ' (2004 ) 127 Gastroenterology : 1038 -1043.

    • Search Google Scholar
  • Targownik, L. E., Thomson, P. A.: Gastroprotective strategies amond NSAID users. Guidelines for appropriate use in chronic illnesses. Can. Pham. Phys., 2006, 52 , 1100–1105.

    Thomson P. A. , 'Gastroprotective strategies amond NSAID users. Guidelines for appropriate use in chronic illnesses ' (2006 ) 52 Can. Pham. Phys. : 1100 -1105.

    • Search Google Scholar
  • Braunwald, E., Antman, E. M., Beasley, J. W. és mtsai: ACC/AHA guideline update for the management of patients with unstable angina and non-ST elevation myocardial infarction – 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committe on the Management of Patients with Unstable Angina). Circulation, 2002, 106 , 1893–1900.

    Beasley J. W. , 'ACC/AHA guideline update for the management of patients with unstable angina and non-ST elevation myocardial infarction – 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committe on the Management of Patients with Unstable Angina) ' (2002 ) 106 Circulation : 1893 -1900.

    • Search Google Scholar
  • Chan, F. K. L., Ching, J. Y. L., Hung, L. C. T. és mtsai: Clopidrogel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med., 2005, 352 , 238–244.

    Hung L. C. T. , 'Clopidrogel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding ' (2005 ) 352 N. Engl. J. Med. : 238 -244.

    • Search Google Scholar
  • Norgard, N. B., Mathews, K. D., Wall, G. C.: Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann. Pharmacother., 2009, 43 , 1266–1274.

    Wall G. C. , 'Drug-drug interaction between clopidogrel and the proton pump inhibitors ' (2009 ) 43 Ann. Pharmacother. : 1266 -1274.

    • Search Google Scholar
  • Laine, L., Hennekens, C.: Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am. J. Gastroenterol., 2010, 105 , 34–41.

    Hennekens C. , 'Proton pump inhibitor and clopidogrel interaction: fact or fiction? ' (2010 ) 105 Am. J. Gastroenterol. : 34 -41.

    • Search Google Scholar
  • Keeble, J. E., Moore, P. K.: Pharmacology and potential therapeutic applications of nitic oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-doniting drugs. Br. J. Pharmacol., 2002, 137 , 295–310.

    Moore P. K. , 'Pharmacology and potential therapeutic applications of nitic oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-doniting drugs ' (2002 ) 137 Br. J. Pharmacol. : 295 -310.

    • Search Google Scholar
  • Arrigo, F. G., Laghi, L.: Activity and potential role of licofelone in the management of osteoarthritis. Clin. Interv. Aging, 2007, 2 , 73–79.

    Laghi L. , 'Activity and potential role of licofelone in the management of osteoarthritis ' (2007 ) 2 Clin. Interv. Aging : 73 -79.

    • Search Google Scholar
  • Barletta, J. F., Erstad, B. L., Fortune, J. B.: Stress ulcer prophylaxis in trauma patients. Crit. Care, 2002, 6 , 526–530.

    Fortune J. B. , 'Stress ulcer prophylaxis in trauma patients ' (2002 ) 6 Crit. Care : 526 -530.

    • Search Google Scholar
  • Mohebbi, L., Hesch, K.: Stress ulcer prophylaxis in the intensive care unit. Proc. Bayl. Univ. Med. Cent., 2009, 22 , 373–376.

    Hesch K. , 'Stress ulcer prophylaxis in the intensive care unit ' (2009 ) 22 Proc. Bayl. Univ. Med. Cent. : 373 -376.

    • Search Google Scholar